

**Table S1. Bacterial strains**

Bacterial strains	Description	Reference
<b><i>Escherichia coli</i></b>		
DH5α	F-φ80dlacZ Δ(lacZYA-argF) U169 deoRsupE44ΔlacU169 (f80lacZDM15) hsdR17 recA1 endA1 (rk- mk+) supE44gyrA96 thi-1 gyrA69 relA1	[1]
<b><i>Staphylococcus aureus</i></b>		
RN4220	restriction negative strain/MSSA cloning intermediate derived from 8325-4	[2]
COL	Archaic HA-MRSA strain	[3]
COL-ΔkatA	COL <i>katA</i> deletion mutant	[4]
COL-ΔahpC	COL <i>ahpC</i> deletion mutant	This study
COL-Δbcp	COL <i>bcp</i> deletion mutant	This study
COL-Δtpx	COL <i>tpx</i> deletion mutant	This study
COL-ΔperR	COL <i>perR</i> deletion mutant	This study
COL-ΔahpCΔkatA	COL <i>ahpC</i> and <i>katA</i> double deletion mutant	This study
COL pRB473-brx-roGFP2	COL WT expressing Brx-roGFP2 biosensor	[5]
COL-ΔkatA pRB473-brx-roGFP2	COL <i>katA</i> deletion mutant expressing Brx-roGFP2	This study
COL-ΔahpC pRB473-brx-roGFP2	COL <i>ahpC</i> deletion mutant expressing Brx-roGFP2	This study
COL-Δbcp pRB473-brx-roGFP2	COL <i>bcp</i> deletion mutant expressing Brx-roGFP2	This study
COL-ΔahpCΔkatA-pRB473-brx-roGFP2	COL <i>ahpC</i> and <i>katA</i> deletion mutant expressing Brx-roGFP2	This study
COL-Δtpx pRB473-brx-roGFP2	COL <i>tpx</i> deletion mutant expressing Brx-roGFP2	This study
COL-ΔkatA::pRB473-katA	COL <i>katA</i> mutant complemented with pRB473- <i>katA</i>	[4]
COL-ΔahpC::pRB473-ahpC-His	COL <i>ahpC</i> mutant complemented with pRB473- <i>ahpC-His</i>	This study
COL-Δbcp::pRB473-bcp-His	COL <i>bcp</i> mutant complemented with pRB473- <i>bcp-His</i>	This study
COL-Δtpx::pRB473-tpx-His	COL <i>tpx</i> mutant complemented with pRB473- <i>tpx-His</i>	This study
Staphylococcus phage 81		[6]

**Table S2. Plasmids**

Plasmid	Description	Reference
pRB473-Xyl	pRB373-derivative, <i>E. coli/ S. aureus</i> shuttle vector, containing xylose-inducible P <sub>Xyl</sub> promoter, Amp <sup>r</sup> , Cm <sup>r</sup>	[7, 8]
pRB473-Xyl-brx-roGFP2	pRB473-derivative expressing brx- roGFP2 under P <sub>Xyl</sub>	[5]
pRB473-Xyl-katA	pRB473-derivative expressing katA under P <sub>Xyl</sub>	[4]
pRB473-Xyl-ahpC-His	pRB473-derivative expressing His-tagged ahpC under P <sub>Xyl</sub>	This study
pRB473-Xyl-bcp-His	pRB473-derivative expressing His-tagged bcp under P <sub>Xyl</sub>	This study
pRB473-Xyl-tpx-His	pRB473-derivative expressing His-tagged tpx under P <sub>Xyl</sub>	This study

**Table S3. Oligonucleotide primers**

Primer name	Sequence (5' to 3')
pMAD-ahpC-for-BgIII	CGC <u>AGATCT</u> CACTCCTCGATACTTTACAAT
pMAD-ahpC-f1-rev	CTACTAAATCTAAACCAGGTTGCTGTAATGGTAAGATTCTTTG
pMAD-ahpC-f2-for	CAAAGAAATCTTACCATTTACAGAACCTGGTTAGATTAGTAG
pMAD-ahpC-rev-Sall	CCAGTCGACCATCAATCATAGAATGCGTGAT
pMAD-bcp-for-BgIII	CGC <u>AGATCT</u> TTTAGTATATGCACGTGCAA
pMAD-bcp-f1-rev	TGTTTTAAAGTCTTCTATTGTGTGAAATTGTTCTCCTTTGC
pMAD-bcp-f2-for	GCAAAAGGAGAACAAATTCCACACAAATAGAAGAACTAAAAACA
pMAD-bcp-rev-Sall	CCAGTCGACGCTAACCTCGCAGTTCTAGTA
pMAD-tpx-for-BgIII	CGC <u>AGATCT</u> ACGCACGTTACTCAATTACA
pMAD-tpx-f1-rev	TTAAATATTTTGTATGCAGCTAACCTTGAAATGTTATTCAGTCAT
pMAD-tpx-f2-for	ATGACTGAAATAACATTCAAAGGTTAGCTGCATACAAAAATATTAA
pMAD-tpx-rev-Sall	CCAGTCGACCAAGGTAAACACTTCTTTACAGT
pMAD-perR-for-BgIII	CGC <u>AGATCT</u> ATCACTTGAAAGCACATTACCA
pMAD-perR-f1-rev	TCTTGGCATTCTTACAAACTCATTGATTCTATTCAACACTCAT
pMAD-perR-f2-for	ATGAGTGTGAATAGAATCAATGAGTTGAAAGAATGCCAAGA
pMAD-perR-rev-Sall	CCAGTCGACGAATTCAATAGTCAAATTACAC
pRB-ahpC-for-BamHI	TAGGGATCCATTCTAGGAGGAAGATATTATG
pRB-ahpC-rev-KpnI-His	CTCGGTACCTTAGTGATGGTATGGTATGGATTAACTAAATCTAAA
pRB-bcp-for-BamHI	TAGGGATCCAATGAAGAAAAGGTGATTATATG
pRB-bcp-rev-KpnI-His	CTCGGTACCTCAGTGATGGTATGGTATGCCAAAAATGTTTTAAGTTCTT
pRB-tpx-for-BamHI	TAGGGATCCATGCAGGAGGTAAAGTATATGACTGAAATAACATTCAAAG
pRB-tpx-rev-SacI-His	CTCGAGCTTTAGTGATGGTATGGTATGAATATTGTATGCAGC
katA-NB-for	AAAGGTTCTGGTGCATTGG
katA-NB-rev	CTAATACGACTCACTATAGGGAGAAATGTGTTCCACCTGG
ahpC-NB-for	TCCTGCTGACTTCTCATTG
ahpC-NB-rev	CTAATACGACTCACTATAGGGAGAGGTTGCAATGTTAGCGCC

Restriction sites are underlined.

## Supplementary References

- [1] Studier, FW, Moffatt, BA. Use of bacteriophage-T7 RNA-polymerase to direct selective high-level expression of cloned genes. *J Mol Biol* 189(1): 113-130, 1986.
- [2] Kreiswirth, BN, Lofdahl, S, Betley, MJ, O'reilly, M, Schlievert, PM, Bergdoll, MS, Novick, RP. The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. *Nature* 305(5936): 709-712, 1983.
- [3] Shafer, WM, Iandolo, JJ. Genetics of staphylococcal enterotoxin B in methicillin-resistant isolates of *Staphylococcus aureus*. *Infect. Immun.* 25(3): 902-911, 1979.
- [4] Linzner, N, Fritsch, VN, Busche, T, Tung, QN, Loi, VV, Bernhardt, J, Kalinowski, J, Antelmann, H. The plant-derived naphthoquinone lapachol causes an oxidative stress response in *Staphylococcus aureus*. *Free Radic. Biol. Med.* 158:126-136, 2020.
- [5] Loi, VV, Harms, M, Müller, M, Huyen, NTT, Hamilton, CJ, Hochgräfe, F, Pane-Farre, J, Antelmann, H. Real-time imaging of the bacillithiol redox potential in the human pathogen *Staphylococcus aureus* using a genetically encoded bacilliredoxin-fused redox biosensor. *Antioxid. Redox Signal.* 26(15): 835-848, 2017.
- [6] Rosenblum, ED, Tyrone, S. Serology, density, and morphology of staphylococcal phages. *J Bacteriol* 88(6): 1737-1742, 1964.
- [7] Brückner, R, Wagner, E, Götz, F. Characterization of a sucrase gene from *Staphylococcus xylosus*. *J. Bacteriol.* 175(3): 851-857, 1993.
- [8] Pöther, DC, Gierok, P, Harms, M, Mostertz, J, Hochgräfe, F, Antelmann, H, Hamilton, CJ, Borovok, I, Lalk, M, Aharonowitz, Y, Hecker, M. Distribution and infection-related functions of bacillithiol in *Staphylococcus aureus*. *Int. J. Med. Microbiol.* 303(3): 114-123, 2013.

**Table S4. CFU counts for the H<sub>2</sub>O<sub>2</sub> survival assays**

**A)** Average CFU/ml of *S. aureus* COL WT,  $\Delta katA$ ,  $\Delta ahpC$ ,  $\Delta tpx$  and  $\Delta bcp$  mutants and the *ahpC* complemented strain before (0 h) and after 2 and 4 h of exposure to 40 mM H<sub>2</sub>O<sub>2</sub> (The % survival rates are shown in **Fig. 1E**)

Strains	CFU/ml		
	0 h	2 h	4 h
WT	$6.63 \times 10^7 \pm 1.11 \times 10^7$	$2.12 \times 10^7 \pm 1.75 \times 10^7$	$5.28 \times 10^6 \pm 8.07 \times 10^5$
$\Delta katA$	$8.90 \times 10^7 \pm 2.62 \times 10^7$	0	0
$\Delta ahpC$	$7.33 \times 10^7 \pm 1.59 \times 10^7$	$2.37 \times 10^8 \pm 7.51 \times 10^7$	$4.87 \times 10^8 \pm 4.53 \times 10^7$
<i>ahpC</i>	$1.24 \times 10^8 \pm 4.76 \times 10^7$	$2.89 \times 10^8 \pm 3.76 \times 10^7$	$3.59 \times 10^8 \pm 1.28 \times 10^8$
$\Delta tpx$	$2.82 \times 10^7 \pm 2.50 \times 10^7$	$2.44 \times 10^6 \pm 1.20 \times 10^6$	$1.65 \times 10^6 \pm 5.51 \times 10^5$
$\Delta bcp$	$9.57 \times 10^7 \pm 3.57 \times 10^7$	$3.29 \times 10^7 \pm 4.86 \times 10^6$	$1.04 \times 10^7 \pm 2.09 \times 10^6$

**B)** Average CFU/ml of *S. aureus* COL WT, the  $\Delta katA$  and  $\Delta ahpC\Delta katA$  mutants and the *katA* complemented strain before (0 h) and after 2 and 4 h of exposure to 1 mM H<sub>2</sub>O<sub>2</sub>. (The % survival rates are shown in **Fig. 1F**)

Strains	CFU/ml		
	0 h	2 h	4 h
WT	$6.93 \times 10^7 \pm 3.23 \times 10^7$	$2.17 \times 10^8 \pm 7.46 \times 10^7$	$4.90 \times 10^8 \pm 1.98 \times 10^8$
$\Delta katA$	$8.00 \times 10^7 \pm 3.71 \times 10^7$	$2.35 \times 10^7 \pm 7.41 \times 10^6$	$3.41 \times 10^6 \pm 1.81 \times 10^6$
<i>katA</i>	$6.30 \times 10^7 \pm 1.36 \times 10^7$	$8.43 \times 10^7 \pm 1.09 \times 10^7$	$2.46 \times 10^8 \pm 3.99 \times 10^7$
$\Delta ahpC\Delta katA$	$8.87 \times 10^7 \pm 2.71 \times 10^7$	$9.33 \times 10^6 \pm 1.41 \times 10^6$	$3.50 \times 10^5 \pm 3.89 \times 10^5$

**C)** Average CFU/ml of log and stationary phase cells of *S. aureus* COL WT and the  $\Delta katA$  mutant before (0 h) and after 1 and 2 h of exposure to 40 mM H<sub>2</sub>O<sub>2</sub>. (The % survival rates are shown in **Fig. 1G**)

Strains	CFU/ml		
	0 h	1 h	2 h
WT log	$8.93 \times 10^7 \pm 1.16 \times 10^7$	$5.97 \times 10^7 \pm 1.30 \times 10^7$	-
	$6.63 \times 10^7 \pm 1.11 \times 10^7$	-	$2.12 \times 10^7 \pm 1.75 \times 10^7$
WT stat	$1.31 \times 10^9 \pm 3.21 \times 10^8$	$1.40 \times 10^9 \pm 3.36 \times 10^8$	$1.74 \times 10^9 \pm 2.93 \times 10^8$
$\Delta katA$ log	$8.90 \times 10^7 \pm 2.62 \times 10^7$	0	0
$\Delta katA$ stat	$1.13 \times 10^9 \pm 9.28 \times 10^7$	$4.03 \times 10^2 \pm 6.35 \times 10^2$	0

**Table S5. CFU counts for microaerophilic H<sub>2</sub>O<sub>2</sub> priming**

**A)** Average CFU/ml of the naïve (C), primed (P), primed and triggered (PT) and triggered (T) *S. aureus* COL WT and the  $\Delta katA$  mutant during the microaerophilic growth before (0 h) and after 2 and 4 h of exposure to 10 mM H<sub>2</sub>O<sub>2</sub>. (The % survival rates are shown in Fig. 3 D, E)

WT	CFU/ml		
	0 h	2 h	4 h
C	$2.01 \times 10^8 \pm 2.07 \times 10^7$	$2.32 \times 10^8 \pm 8.99 \times 10^6$	$2.29 \times 10^8 \pm 2.06 \times 10^7$
P	$1.93 \times 10^8 \pm 1.79 \times 10^7$	$2.25 \times 10^8 \pm 4.33 \times 10^7$	$2.95 \times 10^8 \pm 1.46 \times 10^7$
PT	$2.39 \times 10^8 \pm 2.57 \times 10^7$	$1.25 \times 10^8 \pm 8.52 \times 10^6$	$1.70 \times 10^8 \pm 3.35 \times 10^7$
T	$2.16 \times 10^8 \pm 1.32 \times 10^7$	$1.44 \times 10^5 \pm 5.00 \times 10^4$	$1.35 \times 10^4 \pm 3.02 \times 10^3$
$\Delta katA$	CFU/ml		
	0 h	2 h	4 h
C	$2.22 \times 10^8 \pm 1.33 \times 10^7$	$2.53 \times 10^8 \pm 4.32 \times 10^7$	$2.42 \times 10^8 \pm 4.23 \times 10^7$
P	$7.87 \times 10^7 \pm 2.51 \times 10^7$	$1.12 \times 10^8 \pm 3.34 \times 10^7$	$8.93 \times 10^7 \pm 1.61 \times 10^7$
PT	$5.64 \times 10^7 \pm 1.98 \times 10^7$	$7.50 \times 10^0 \pm 8.29 \times 10^0$	0
T	$2.50 \times 10^8 \pm 1.98 \times 10^7$	$1.50 \times 10^1 \pm 2.06 \times 10^1$	0

**B)** Average CFU/ml of the naïve (C), primed (P), primed and triggered (PT) and triggered (T) *S. aureus* COL *katA* complemented strain during the microaerophilic growth under before (0 h) and after 2 and 4 h of exposure to 10 mM H<sub>2</sub>O<sub>2</sub>.

(The % survival rates are shown in Fig. S4C)

katA	CFU/ml		
	0 h	2 h	4 h
C	$1.58 \times 10^8 \pm 3.06 \times 10^7$	$1.57 \times 10^8 \pm 6.26 \times 10^6$	$1.71 \times 10^8 \pm 3.52 \times 10^7$
P	$1.63 \times 10^8 \pm 2.12 \times 10^7$	$1.55 \times 10^8 \pm 2.35 \times 10^7$	$1.92 \times 10^8 \pm 4.22 \times 10^7$
PT	$1.70 \times 10^8 \pm 2.27 \times 10^7$	$4.91 \times 10^3 \pm 3.12 \times 10^3$	$4.24 \times 10^2 \pm 2.87 \times 10^2$
T	$1.59 \times 10^8 \pm 2.90 \times 10^7$	$1.75 \times 10^3 \pm 9.17 \times 10^2$	$4.20 \times 10^2 \pm 3.35 \times 10^2$

**Table S6. CFU counts for aerobic H<sub>2</sub>O<sub>2</sub> priming**

**A)** Average CFU/ml of the naïve (C), primed (P), primed and triggered (PT) and triggered (T) *S. aureus* COL WT during the aerobic growth before (0 h) and after 2 and 4 h of exposure to 10 mM H<sub>2</sub>O<sub>2</sub>. (The % survival rates are shown in Fig. 4C)

WT	CFU/ml		
	0 h	2 h	4 h
C	$6.01 \times 10^7 \pm 6.12 \times 10^6$	$3.45 \times 10^8 \pm 1.83 \times 10^7$	$1.04 \times 10^9 \pm 2.98 \times 10^8$
P	$5.31 \times 10^7 \pm 1.49 \times 10^7$	$3.02 \times 10^8 \pm 7.17 \times 10^7$	$1.01 \times 10^9 \pm 3.15 \times 10^8$
PT	$5.31 \times 10^7 \pm 1.49 \times 10^7$	$4.32 \times 10^7 \pm 2.23 \times 10^7$	$1.03 \times 10^8 \pm 4.44 \times 10^7$
T	$6.01 \times 10^7 \pm 6.12 \times 10^6$	$3.60 \times 10^7 \pm 1.34 \times 10^7$	$7.68 \times 10^7 \pm 4.19 \times 10^7$

**B)** Average CFU/ml of the naïve (C), primed (P), primed and triggered (PT) and triggered (T) *S. aureus* COL WT during the aerobic growth before (0 h) and after 2 and 4 h of exposure to 40 mM H<sub>2</sub>O<sub>2</sub>. (The % survival rates are shown in Fig. 4F)

WT	CFU/ml		
	0 h	2 h	4 h
C	$6.08 \times 10^7 \pm 4.01 \times 10^6$	$4.46 \times 10^8 \pm 1.45 \times 10^8$	$9.17 \times 10^8 \pm 2.08 \times 10^8$
P	$5.44 \times 10^7 \pm 9.86 \times 10^6$	$2.03 \times 10^8 \pm 3.29 \times 10^7$	$5.35 \times 10^8 \pm 1.21 \times 10^8$
PT	$5.44 \times 10^7 \pm 9.86 \times 10^6$	$4.58 \times 10^6 \pm 1.93 \times 10^6$	$5.74 \times 10^5 \pm 5.09 \times 10^5$
T	$6.08 \times 10^7 \pm 4.01 \times 10^6$	$6.99 \times 10^6 \pm 2.95 \times 10^6$	$3.18 \times 10^6 \pm 1.01 \times 10^6$

**Table S7. CFU counts for the CHP survival assays**

Average CFU/ml of the *S. aureus* COL WT, the  $\Delta katA$ ,  $\Delta ahpC$ ,  $\Delta tpx$  and  $\Delta bcp$  mutants and complemented strains before (0 h) and after 2 and 4 h of exposure to 40 mM H<sub>2</sub>O<sub>2</sub>.

(The % survival rates are shown in Fig. 6G, H)


Strains	CFU/ml		
	0 h	2 h	4 h
COL WT	$6.70 \times 10^7 \pm 1.98 \times 10^7$	$2.46 \times 10^7 \pm 1.12 \times 10^7$	$2.95 \times 10^7 \pm 1.54 \times 10^7$
$\Delta katA$	$1.23 \times 10^8 \pm 5.19 \times 10^7$	$1.48 \times 10^8 \pm 2.52 \times 10^7$	$1.65 \times 10^8 \pm 8.26 \times 10^7$
$\Delta ahpC$	$6.87 \times 10^7 \pm 1.92 \times 10^7$	$2.37 \times 10^7 \pm 6.87 \times 10^6$	$5.95 \times 10^6 \pm 3.93 \times 10^6$
$\Delta tpx$	$2.30 \times 10^7 \pm 2.32 \times 10^7$	$5.30 \times 10^6 \pm 3.70 \times 10^6$	$2.31 \times 10^6 \pm 1.77 \times 10^6$
$\Delta bcp$	$7.37 \times 10^7 \pm 1.14 \times 10^7$	$1.72 \times 10^7 \pm 6.26 \times 10^6$	$7.62 \times 10^6 \pm 6.08 \times 10^6$
<i>katA</i>	$9.83 \times 10^7 \pm 6.04 \times 10^7$	$9.46 \times 10^7 \pm 5.27 \times 10^7$	$8.77 \times 10^7 \pm 4.71 \times 10^7$
<i>ahpC</i>	$1.32 \times 10^8 \pm 1.47 \times 10^7$	$6.97 \times 10^7 \pm 4.60 \times 10^7$	$4.40 \times 10^7 \pm 1.27 \times 10^7$
<i>tpx</i>	$9.65 \times 10^7 \pm 2.35 \times 10^7$	$3.42 \times 10^7 \pm 2.05 \times 10^7$	$4.23 \times 10^7 \pm 2.04 \times 10^7$
<i>bcp</i>	$1.14 \times 10^8 \pm 2.95 \times 10^7$	$4.22 \times 10^7 \pm 1.73 \times 10^7$	$3.71 \times 10^7 \pm 8.71 \times 10^6$

**Table S8. CFU counts for HOCl survival assays**

Average CFUs/ml of the *S. aureus* COL WT and  $\Delta katA$ ,  $\Delta ahpC$ ,  $\Delta tpx$  and  $\Delta bcp$  mutant strains before (0 h) and after 2 and 4 h of exposure to 2.5 mM HOCl.


(The % survival rates are shown in Fig. S5E)

Strains	CFU/ml		
	0 h	2 h	4 h
COL WT	$7.84 \times 10^7 \pm 1.39 \times 10^7$	$3.93 \times 10^7 \pm 1.05 \times 10^7$	$1.26 \times 10^7 \pm 2.69 \times 10^6$
$\Delta katA$	$1.14 \times 10^8 \pm 5.24 \times 10^7$	$5.75 \times 10^7 \pm 3.78 \times 10^7$	$1.92 \times 10^7 \pm 1.36 \times 10^7$
$\Delta ahpC$	$7.23 \times 10^7 \pm 1.45 \times 10^7$	$2.71 \times 10^7 \pm 5.98 \times 10^6$	$1.45 \times 10^7 \pm 1.54 \times 10^6$
$\Delta tpx$	$3.41 \times 10^7 \pm 2.52 \times 10^7$	$1.47 \times 10^7 \pm 1.05 \times 10^7$	$6.94 \times 10^6 \pm 8.04 \times 10^6$
$\Delta bcp$	$1.00 \times 10^8 \pm 2.76 \times 10^7$	$3.75 \times 10^7 \pm 1.49 \times 10^7$	$2.70 \times 10^7 \pm 1.08 \times 10^7$

**Fig. S1**


**Fig. S1. Complementation of KatA increases the H<sub>2</sub>O<sub>2</sub> resistance in *S. aureus* (A-C), but the catalase activity in the *katA* complemented strain is lower compared to the WT (D).** Growth curves of the *S. aureus* COL WT (A), the  $\Delta$ *katA* mutant (B) and the *katA* complemented strain (C) after exposure to 0.4 and 1 mM H<sub>2</sub>O<sub>2</sub> stress at an OD<sub>500</sub> of 0.5. Mean values and SD of four biological replicates are presented. (D) Catalase staining of aerobically grown *S. aureus* COL WT, the  $\Delta$ *katA* mutant and the *katA* complemented strain before (co) and after exposure to 100  $\mu$ M H<sub>2</sub>O<sub>2</sub> at an OD<sub>500</sub> of 0.5. Protein extracts were separated by native PAGE and the catalase activity was determined using diaminobenzidine staining as described in the Methods. The statistics is shown below the graphs and was calculated using the Student's unpaired two-tailed t-test by the graph prism software for co vs. 0.4 mM and co vs. 1 mM H<sub>2</sub>O<sub>2</sub>. Symbols are ns p > 0.05, \*p ≤ 0.05 , \*\*p ≤ 0.01 and \*\*\*p ≤ 0.001.

**Fig. S2**




**Fig. S2. Growth and catalase activity of the *ahpC* complemented strain.** (A) Growth curves of *S. aureus* COL  $\Delta$ *ahpC* mutant and *ahpC* complemented strains in RPMI medium before (co) and after exposure to 10 mM  $H_2O_2$  (A). Mean values and SD of 4 biological replicates are presented. The statistics was determined using a Student's unpaired two-tailed t-test by graph prism. Symbols are: ns  $p > 0.05$  (B) Catalase staining shows higher catalase activity in the  $\Delta$ *ahpC* mutant and *ahpC* complemented strain compared to the WT at control conditions.

**Fig. S3**




**Fig. S3. The  $\Delta katA$   $ahpC$  double mutant is hypersensitive towards  $H_2O_2$  and delayed in recovery of the  $E_{BSH}$  after 0.4 mM  $H_2O_2$**  (A) Growth curves of *S. aureus* COL WT and the  $\Delta ahpC\Delta katA$  double mutant in RPMI medium before (co) and after exposure to 10 mM  $H_2O_2$  at an  $OD_{500}$  of 0.5. The survival rates were calculated relative to the untreated control, which was set to 100%. Mean values and SD of 3-4 biological replicates are shown. The statistics was calculated using the Student's unpaired two-tailed t-test by the graph prism software. Symbols are \* $p \leq 0.05$ , \*\* $p \leq 0.01$  and \*\*\* $p \leq 0.001$ . (B) The Brx-roGFP2 biosensor in the *S. aureus* COL  $\Delta ahpC\Delta katA$  double mutant showed a fast oxidation and a delay in recovery of the reduced  $E_{BSH}$  after 0.4 mM  $H_2O_2$ . The oxidation degree (OxD) of the Brx-roGFP2 response was calculated based on the 405/488 nm excitation ratios and normalized to fully reduced and oxidized controls. Mean values and SD of the OxD values are presented from 3 biological replicates.

**Fig. S4**




**Fig. S4.** The *katA* complemented strain is not primable towards increased  $\text{H}_2\text{O}_2$  resistance during the microaerophilic growth. **(A)** Setup for microaerophilic priming and triggering experiments. The *S. aureus* *katA* complemented strain was primed during the log phase with  $0.1 \text{ mM H}_2\text{O}_2$  for  $\sim 30 \text{ min}$  (**P**) and subsequently treated with  $10 \text{ mM H}_2\text{O}_2$  as triggering stimulus (**PT**). The growth curves (**B**) and survival rates (**C**) were determined in naïve (**C**), primed (**P**), primed and triggered (**PT**) and triggered cells (**T**). The survival rates were calculated after 2 and 4 h of  $\text{H}_2\text{O}_2$  stress relative to untreated control cells. The results are from 3-4 biological replicates. Error bars represent the SD. The statistics was determined using a Student's unpaired two-tailed t-test by graph prism. Symbols are: ns  $p > 0.05$ .


**Fig. S5**




**Fig. S5. KatA and the peroxiredoxins AhpC, Tpx and Bcp are not involved in HOCl detoxification in *S. aureus*.** **(A-C)** Growth curves of *S. aureus* COL WT,  $\Delta katA$  (**A**),  $\Delta ahpC$  (**B**),  $\Delta tpx$  (**C**) and  $\Delta bcp$  mutants (**D**) in RPMI medium before (co) and after exposure to 1.5 mM HOCl stress during the log phase. **(D)** Survival rates were determined as CFUs of *S. aureus* COL WT,  $\Delta katA$ ,  $\Delta ahpC$ ,  $\Delta tpx$  and  $\Delta bcp$  mutants at 2 and 4 h after treatment with 2.5 mM HOCl. Survival of the untreated control was set to 100%. Mean values and SD of 4-5 biological replicates are presented. The statistics was determined using a Student's unpaired two-tailed t-test by graph prism. Symbols are: ns  $p > 0.05$ , \* $p \leq 0.05$

**Fig. S6**

**Fig. S6. A)** The Northern blot images using the *katA* specific RNA probe show the *katA* transcripts (images of Fig. 1H, 2 bioreplicates, 3 technical replicates). **B)** The methylen blue stain of the Northern blots used as loading control for total RNA (images of Fig. 1H, 2 bioreplicates, 3 technical replicates). Labelling of RNA samples is as above for the detection of the *katA* transcript. The bands for the 16S and 23S rRNAs are indicated.

**Fig. S7**

**Fig. S7.** **A)** The Northern blot images using the *ahpC* specific RNA probe show the *ahpCF* operon transcripts (images of Fig. 1H, 2 bioreplicates, 3 technical replicates). **B)** The methylene blue stain of the Northern blots used as loading control for total RNA (images of Fig. 1H, 2 bioreplicates, 3 technical replicates). Labelling of RNA samples is as above for the detection of the *ahpCF* transcript. The bands for the 16S and 23S rRNAs are indicated.



**Fig. S8**

**Fig. S8. A)** The Northern blot images using the *dps* specific RNA probe show the *dps* transcripts (images of Fig. 1H, 2 bioreplicates, 3 technical replicates). **B)** The methylene blue stain of the Northern blots used as loading control for total RNA (images of Fig. 1H, 2 bioreplicates, 3 technical replicates). Labelling of RNA samples is as above for the detection of the *dps* transcript. The bands for the 16S and 23S rRNAs are indicated.



**Fig. S9**

## microaerophilic

Biorep 1				Biorep 2				Biorep 3						
C1	C2	P	PT	T	C1	C2	P	PT	T	C1	C2	P	PT	T

***katA***23S rRNA  
16S rRNA

Biorep 1				Biorep 2				Biorep 3						
C1	C2	P	PT	T	C1	C2	P	PT	T	C1	C2	P	PT	T


***katA***23S rRNA  
16S rRNA

**Fig. S9. A)** The Northern blot images of priming experiments using the *katA* specific RNA probe show the *katA* transcripts (images of Fig. 5B,C, 3 bioreplicates). **B)** The methylen blue stain of the Northern blots used as loading control for total RNA (images of Fig. 5B,C; 3 bioreplicates). Labelling of RNA samples is as above for the detection of the *katA* transcript. The bands for the 16S and 23S rRNAs are indicated.

**Fig. S10**



**microaerophilic**

Biorep 1				Biorep 2				Biorep 3						
C1	C2	P	PT	T	C1	C2	P	PT	T	C1	C2	P	PT	T






**aerobic**

Biorep 1				Biorep 2				Biorep 3						
C1	C2	P	PT	T	C1	C2	P	PT	T	C1	C2	P	PT	T



**Fig. S10. A)** The Northern blot images of priming experiments using the *ahpC* specific RNA probe show the *ahpCF* transcripts (images of Fig. 5B,C; 3 bioreplicates). **B)** The methylen blue stain of the Northern blots used as loading control for total RNA (images of Fig. 5B,C; 3 bioreplicates). Labelling of RNA samples is as above for the detection of the *ahpCF* transcript. The bands for the 16S and 23S rRNAs are indicated.

**Fig. S11**




**Fig. S11.** Native gels of catalase stains used for KatA activity assays (images of Fig. 5F; 2 bioreplicates, 2 technical replicates)

**Fig. S12**

**Biorep 1**

WT		<i>katA</i>		$\Delta katA$	
C2	P	C2	P	C2	



**Biorep 2**

WT		<i>katA</i>		$\Delta katA$	
C2	P	C2	P	C2	




**Biorep 3**

WT		<i>katA</i>		$\Delta katA$	
C2	P	C2	P	C2	



**Fig. S12.** Native gels of catalase stains used for KatA activity assays (images of Fig. S1D; 3 bioreplicates)

**Fig. S13**



**Fig. S13.** Native gels of catalase stains used for KatA activity assays (images of Fig. S2B; 3 bioreplicates)